Indonesian Journal of Clinical Pharmacy最新文献

{"title":"Evaluasi Kualitas Hidup Pasien Parkinson Berdasarkan Terapi Berbasis Levodopa","authors":"Yasinda Oktariza, Lia Amalia, Sobaryati Sobaryati, M. Y. Kurniawati","doi":"10.15416/ijcp.2019.8.4.246","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.4.246","url":null,"abstract":"","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124108087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selenium sebagai Suplemen Terapi Kanker: Sebuah Review","authors":"Eli Mirdayani, I. M. Puspitasari, Rizky Abdulah, Anas Surbanas","doi":"10.15416/ijcp.2019.8.4.301","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.4.301","url":null,"abstract":"Selenium is an essential element of micronutrients for human health. In the body, selenium is spread in all organs in the form of a conjugated protein compound (selenoprotein). The compound contains at least a selenocysteine consisting of cysteine. Selenoprotein compounds are generally antioxidants. Selenium is linked to its effects on human health including some types of cancer. Studies on the use of selenium supplementation in cancer therapy with radiation and chemotherapy showed elevated plasma selenium levels, increased therapeutic efficacy, reduced side effects, and improved quality of life for cancer patients. This review aimed to investigate and evaluate the utilization of selenium as a supplement in cancer treatment for patients who undergoing radiotherapy and chemotherapy. Database searching was performed through PubMed, Science Direct and Google Scholar using the keywords “Selenium”, “Selenoprotein”, “Selenium and cancer therapy”, “Selenium and Chemotherapy” and “Selenium and Radiotherapy”. The results showed that selenium is a micronutrient that can be developed as a supplement component in the prevention of cancer with a therapeutic dose of 100–400 micrograms per day.","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116808697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hubungan Pemilihan Obat dan Keberhasilan Terapi Pasien Rheumatoid Arthritis","authors":"Shifa A. Savitri, Pudjiastuti Kartidjo, A. R. Rahmadi, S. N. Vikasari","doi":"10.15416/ijcp.2019.8.4.237","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.4.237","url":null,"abstract":"","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130092394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efikasi Afatinib dan Gefitinib pada Pasien Non-small Cell Lung Cancer EGFR Mutasi Positif: Tinjauan Sistematis","authors":"S. Sari, T. Andayani, Dwi Endarti, Kartika Widayati","doi":"10.15416/ijcp.2019.8.4.289","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.4.289","url":null,"abstract":"Tyrosine kinase inhibitors (TKIs) have been recommended by the National Comprehensive Cancer Networks (NCCN) as first-line therapy in non-small cell lung cancer (NSCLC) with EGFR mutation, namely gefitinib (first generation) and afatinib (second generation). Several studies have been conducted related to the efficacy of these TKIs, but few have conducted systematic reviews specifically afatinib and gefitinib. This systematic review aimed to provide a comprehensive overview of the efficacy of gefitinib and afatinib as first-line therapy. To identify the relevant studies, it used several databases such as Science Direct, PubMed, and Google Scholar. The review was limited to the randomized control trial study, the use of afatinib and gefitinib as first-line therapy, the use of afatinib and gefitinib as monotherapy, and articles written in the English language. An electronic data-based search identified 2089 articles; 48 articles matched the title and abstract, yet only 8 articles met the inclusion to be reviewed. In general, the efficacy of afatinib and gefitinib is more effective than platinum-based chemotherapy as showed that the progression-free survival of these medications is longer than platinum-based chemotherapy. Although the overall survival value is not better than platinum-based chemotherapy, afatinib inhibits the tumor growth better compared to gefitinib. Common side-effects in afatinib and gefitinib include rashes and diarrhea, while neutropenia, nausea, and anemia commonly occur in platinum-based chemotherapy. Afatinib and gefitinib offer better efficacy compared to platinum-based chemotherapy. Specifically, the afatinib has greater efficacy compared to gefitinib in first-line therapy for patient with NSCLC EGFR mutation. Keyword: Afatinib, efficacy, gefitinib, non-small cell lung cancer Korespondensi: Seftika Sari, MPH., Apt., Sekolah Tinggi Ilmu Farmasi Riau, Pekanbaru, Riau 28289, Indonesia, email: seftika1987.apt@gmail.com Naskah diterima: 9 Februari 2019, Diterima untuk diterbitkan: 15 Juli 2019, Diterbitkan: 28 Desember 2019 Jurnal Farmasi Klinik Indonesia, Desember 2019 Tersedia online pada: Vol. 8 No. 4, hlm 289–300 http://ijcp.or.id ISSN: 2252–6218 DOI: 10.15416/ijcp.2019.8.4.289 Jurnal Farmasi Klinik Indonesia Volume 8, Nomor 4, Desember 2019","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125652461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analisis Penggunaan Antibiotik pada Pasien Rawat Inap Bedah dengan Menggunakan Defined Daily Dose dan Drug Utilization 90% di Rumah Sakit Universitas Airlangga","authors":"N. I. Pratama, Budi Suprapti, A. O. Ardhiansyah, D. Shinta","doi":"10.15416/ijcp.2019.8.4.256","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.4.256","url":null,"abstract":"","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124418396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pola Penanda Glikemik dan Inflamasi dalam Perkembangan Penyakit Diabetes Melitus Tipe 2 pada Pria Obesitas Sentral","authors":"Miftakhur Rahman, Indriyanti Rafi Sukmawati, I. M. Puspitasari","doi":"10.15416/ijcp.2019.8.4.281","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.4.281","url":null,"abstract":"","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129482679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analisis Efektivitas Biaya Penggunaan Antibiotik pada Pasien Community-acquired Pneumonia di RSUP Dr. Hasan Sadikin Bandung","authors":"Mia N. A. Fatin, Cherry Rahayu, Auliya A. Suwantika","doi":"10.15416/ijcp.2019.8.3.228","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.3.228","url":null,"abstract":"","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129359247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pengukuran Risiko Gangguan Tidur pada Penggunaan Angiotensin Converting Enzyme Inhibitor dan Calcium Channel Blocker: Case Control Study di Puskesmas Dau, Malang","authors":"M. Aditya, Rehmadanta Sitepu, Dion Notario, Fibe Y. Cesa","doi":"10.15416/ijcp.2019.8.3.166","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.3.166","url":null,"abstract":"Sleep disorder or insomnia arisen in hypertensive patients might be derived as a side effect of antihypertensive mediations such as Angiotensin Converting Enzyme Inhibitor (ACEI) and Calcium Channel Blocker (CCB), but the influence of each group had not been much compared. Therefore, a research was conducted using case control design to assess the risk of using ACEI and CCB against the incidence rate of insomnia. Demographic data and insomnia status were collected through Data Collector Sheet and Athens Insomnia Scale (AIS) questionnaire before univariate, bivariate, and multivariate analysis was conducted. The result showed that in the age group of 56–60 years patients undergoing treatment with ACEI have a smaller risk of insomnia of approximately 0.38 times (p=0.026, 95% CI=0.15–0.94) compared to the other patients who were treated with CCB, while in other categorial groups, no significant relationship was found. Thus, the monitoring of insomnia side effects becomes important to be conducted by healthcare professional especially in patients undergoing treatment with CCB at the ages of 56–60 years.","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"96 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121531743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profil Penatalaksanaan Kanker Serviks Stadium IIB–IIIB dengan Terapi Radiasi dan Kemoradiasi di Rumah Sakit Umum Pusat Dr. Hasan Sadikin Bandung Periode Tahun 2015–2017","authors":"Dewi Legianawati, I. M. Puspitasari, Auliya A. Suwantika, Adji Kusumadjati","doi":"10.15416/ijcp.2019.8.3.205","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.3.205","url":null,"abstract":"","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116242088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pengaruh Index Masa Tubuh Terhadap Respon Klopidogrel Pada Pasien Sindrom Koroner Akut Dengan Intervensi Koroner Perkutan Di RSUPN Dr. Cipto Mangunkusumo Jakarta","authors":"Marlina Qurratul Aini, Retnosari Andrajati, Rina Mutiara","doi":"10.15416/ijcp.2019.8.3.157","DOIUrl":"https://doi.org/10.15416/ijcp.2019.8.3.157","url":null,"abstract":"Tindakan Intervensi Koroner Perkutan (IKP) memiliki risiko trombosis yang menyebabkan gangguan kardiovaskular. Gangguan kardiovaskular dievaluasi dengan menggunakan Major Adverse Cardiac Event (MACE). Terapi pencegahan trombosis menggunakan dual antiplatelet, yakni asetosal dan klopidogrel. Klopidogrel merupakan obat dengan variabilitas farmakokinetik dan farmakodinamik yang tinggi pada setiap individu, salah satunya dipengaruhi oleh Indeks Massa Tubuh (IMT). Subjek dengan nilai IMT ≥25 kg/m2 emiliki nilai agregasi platelet lebih besar dibanding subjek dengan IMT","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"391 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120886105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}